Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy

Download
Citations
Altmetric
Author
Kelly, GL; Strasser, AEditor
Jacks, T; Sawyers, CLDate
2020-01-01Source Title
ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4Publisher
ANNUAL REVIEWSAffiliation
Medical Biology (W.E.H.I.)Metadata
Show full item recordDocument Type
ChapterCitations
Kelly, G. L. & Strasser, A. (2020). Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy. Jacks, T (Ed.). Sawyers, CL (Ed.). ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 4, pp.299-313. ANNUAL REVIEWS.Access Status
Open AccessAbstract
<jats:p> Apoptosis is critical for embryonic development, tissue homeostasis, and the removal of infected or otherwise dangerous cells. It is controlled by three subgroups of the BCL-2 protein family—the BH3-only proteins that initiate cell death; the effectors of cell killing, BAX and BAK; and the antiapoptotic guardians, including MCL-1 and BCL-2. Defects in apoptosis can promote tumorigenesis and render malignant cells refractory to anticancer therapeutics. Activation of cell death by inhibiting antiapoptotic BCL-2 family members has emerged as an attractive strategy for cancer therapy, with the BCL-2 inhibitor venetoclax leading the way. Large-scale cancer genome analyses have revealed frequent amplification of the locus encoding antiapoptotic MCL-1 in human cancers, and functional studies have shown that MCL-1 is essential for the sustained survival and expansion of many types of tumor cells. Structural analysis and medicinal chemistry have led to the development of three distinct small-molecule inhibitors of MCL-1 that are currently undergoing clinical testing. </jats:p>
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
Collections
- Minerva Elements Records [53102]
- Medical Biology - Research Publications [1415]